论文部分内容阅读
日本札幌医大第四内科的漆崎教授和高俊裕讲师利用癌患者本身的淋巴细胞与T 细胞增殖因子IL—2,在特殊的试管装置内,成功地培养出一种对癌细胞有抑制和吞噬功能的抗癌细胞LAK。漆崎指出,原来把IL—2因子单独注入癌患者体内,但由于IL—2因子在体内滞留时间很短,影响疗效。而用患者本身的淋巴细胞在体外培养抗癌细胞(LAK)再注入癌患者体内,使癌治疗又取得重大突破,临床试用结果表明,患者每周注入1～2次,3～
Prof. Akira Kizosaki and Prof. Taka Junyu of the Fourth Department of Internal Medicine at the Medical College of Sapporo, Japan, used cancer cells and their lymphocytes and T cell proliferation factor IL-2 to successfully develop a suppressive and phagocytic effect on cancer cells in a special test tube device. Anti-cancer cells LAK. Chisaki pointed out that the IL-2 factor was originally injected into cancer patients alone, but because IL-2 factors stay in the body for a very short time, affect the efficacy. The patient’s own lymphocytes were used to culture anti-cancer cells (LAK) in vitro and then reinjected into patients with cancer, making a major breakthrough in cancer treatment. Clinical trial results showed that patients were injected 1 to 2 times a week, 3 to 3 times.